Abstract
ON101 is a topical macrophage-regulation new drug for diabetic foot ulcers (DFUs) with superior efficacy to the standard care dressing in a large Phase 3 clinical trial. We evaluated if a desirable outcome could be achieved using ON101 as the standard of care for a DFU with toe gangrene and osteomyelitis in a real-world setting. A 77-year-old male with type 2 diabetes (HbA1c 7.2%), peripheral artery disease (PAD), chronic kidney disease (CKD) stage 3, and coronary artery disease had a persisted DFU for 8 months.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call